Review of Foreign Investment in the U.S. Pharmaceutical Supply Chain
This Act mandates the Federal Trade Commission (FTC) to annually report on the impact of foreign investment on the U.S. pharmaceutical industry. The goal is to assess how reliance on foreign manufacturing affects the domestic capacity to produce drugs and their ingredients. Citizens will gain better insight into the security and stability of their medicine supply, potentially leading to future actions aimed at reducing shortage risks.
Key points
The FTC must annually prepare a report on foreign investment in the U.S. pharmaceutical industry.
The report will assess the effect of concentration and reliance on foreign manufacturing on domestic drug production capacity.
The analysis will also cover the impact of foreign investment in DNA sequencing and storage technologies.
An unclassified summary of the report must be published publicly by the FTC for transparency.
Expired
Citizen Poll